ArticleNutrition journal2025
China precision nutrition biobank: protocol of a prospective cohort study on diet, human phenotype/genotype, and early-onset chronic diseases.
Article in Nutrition journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundThe global burden of early-onset chronic diseases, especially early-onset type 2 diabetes, is increasing, particularly in China. Diet is a key factor and emerging evidence highlights substantial inter-individual variability in metabolic responses to diets, highlighting the need for precision nutrition.
methodsThe China Precision Nutrition Biobank (CPNB) is a prospective, longitudinal, cohort study designed to investigate diet-phenotype/genotype interactions and develop precision dietary strategies for early prevention and intervention of chronic diseases, with a particular focus on early-onset diseases. CPNB consists of three phases: the alpha (pilot cohort), beta (transition cohort), and gamma (main cohort) phases. Approximately 200, 1450, and 20,000 adults aged 18-40 years from urban and rural areas in China including Beijing, one city each in Heilongjiang, Shandong, Zhejiang, Guangxi, and Hainan provinces, and one or more villages each in Henan, Gansu, Sichuan, Zhejiang, and Hunan provinces will be recruited during the alpha, beta, and gamma phases, respectively, between 2025 and 2035. Sociodemographic information, medical records, read-time weighed food records and corresponding continuous glucose monitor (CGM) readings, objective physical activity, food challenges, genes, gut and oral microbiota, metabolites from blood, stool, urine, saliva, and hair, and questionnaires will be collected at baseline survey. The follow-up survey will be conducted every five years to repeat these assessments until participants' death (the follow-up period may extend up to 80 years). Outcomes of interest are common early- and late-onset chronic diseases and their preclinical stages. DISCUSSION: The CPNB data can be used to develop prediction models for personalized metabolic responses and risks of early-onset chronic diseases among Chinese people. It will also provide new evidence on interactions of diet with human phenotypes/genotypes during preclinical stage, onset, and progression of early-onset diseases. CPNB aims to inform the development of precision nutrition strategies aligned with the principles of predictive, personalized, preventive, and participatory medicine in the Chinese population.
trial registrationCPNB was registered at Chinese Clinical Trial Registry ( http://www.chictr.org.cn/ ) on June 3rd, 2025, under the registration number ChiCTR2500103621.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.